May 24,2022

An examination of depression, anxiety, and fear of recurrence among cancer survivors who participated in a virtual cognitive behavioral therapy (CBT)-based telephone coaching program

Depression, anxiety, and fear of recurrence (FOR) are prevalent among cancer survivors, and it is recommended that they have access to supportive services and resources to address psychosocial needs during follow-up care. This study examined the impact of a virtual cognitive behavioral therapy (CBT)-based telephone coaching program (BounceBack®) on depression, anxiety, and FOR.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
May 24,2022

Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. The CDx pan-cancer indication will allow identification of cancer patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusions including NTRK1, NTRK2 or NTRK3, and may benefit from targeted therapy with Bayer's VITRAKVI® (larotrectinib), in accordance with the approved therapeutic labeling.

PRODUCT

#cdx

View Analyst & Ambassador Comments
Go to original news
May 27,2022

DoMore Diagnostics wins CE mark for AI algorithm that predicts colorectal cancer outcomes

DoMore Diagnostics announced that it received CE mark approval in Europe for its Histotype Px Colorectal deep learning algorithm. Oslo, Norway-based DoMore designed its Histotype Px Colorectal deep learning algorithm to predict colorectal cancer patient outcomes based on analysis of digital histology images.

REGULATORY CE MARK

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 01,2022

Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2022 Annual Meeting

Flatiron Health® today announced three Flatiron-authored abstracts have been accepted for poster discussion and presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 12,2022

Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer

Novartis highlights data from across its oncology portfolio at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2022 Hybrid Congress. With nearly 130 abstracts from Novartis-sponsored and investigator-initiated trials accepted, the data showcase research across over 20 compounds in key disease areas, including breast, lung and prostate cancers, leukemia, lymphoma, multiple myeloma and other blood disorders.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 13,2022

AI-Powered oncology platform raises $35 million Series C funding round

OncoHost has announced a Series C $35 million funding round led by ALIVE Israel HealthTech VC, as well as other prominent investors. The funding will go towards expanding OncoHost’s ongoing multicenter PROPHETIC trial (Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments) as well as support its upcoming US commercial launch.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
May 13,2022

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will share new research during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 and the European Hematology Association (EHA) 2022 Hybrid Congress from June 9-12. A total of 13 abstracts from the company’s expanding portfolio of approved and investigational therapies will be presented across both meetings, underscoring the company’s commitment to advancing treatment options for advanced and rare cancers, including prostate, pancreatic and urothelial cancer, as well as acute myeloid leukemia (AML).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 16,2022

Digital health new and, funding roundups

GE Healthcare entered to an agreement with Alliance Medical to create a digital solution with the aim to enhance productivity within hospital radiology departments in the UK. Using advanced data analytics and AI, the companies will bring together tools to streamline daily management and enable proactive problem-solving to help prevent issues for staff and their patients.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 18,2022

Miami Cancer Institute Takes Action To Address Inequities in Cancer Care with Expanded COTA, Inc. Collaboration

COTA, Inc. and Miami Cancer Institute, part of Baptist Health South Florida, announced today they are expanding their real-world data (RWD) and analytics partnership. Miami Cancer Institute will use COTA’s Real-World Analytics platform (RWA) to better understand how certain patient demographics, such as zip code, ethnicity, or other socio-economic factors, contribute to unwanted disparities in patient outcomes.

COLLABORATION PARTNERSHIP

#institution

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Jun 02,2022

Results presented at ASCO 2022: patient-reported symptom data can predict antibody levels against SARS-COV-2 on vaccinated cancer patients

Research conducted at the University Hospital Geneva aimed to investigate the potential correlation between symptom burden reported through electronic patient-reported outcomes (ePRO) and the serological response to SARS-CoV-2 vaccines on cancer patients. The promising results are presented at ASCO 2022 this week.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY